Gene Test Shows Risk of Recurrence of Stage II Colon Cancer

The first genomic test to predict whether or not stage II colon cancer will recur has been developed and validated in a large number of tumor tissue samples from patients in the United States and the United Kingdom.  The 12 gene assay can reliably predict whether an individual patient has a low, intermediate, or high risk of having their cancer return.

Doctors and patients will be able to use the Recurrence Score, along with other clinical indicators, to decide whether further chemotherapy treatment after surgery should be considered or whether they can safely skip chemo and its risks.

However, the study was not able to link recurrence scores with benefits from 5-FU and leucovorin chemotherapy.

Researchers from the National Surgical Adjuvant Breast and Bowel Project (NSABP) and the Cleveland Clinic analyzed tumor samples saved from 1,850 patients enrolled in clinical trials for 761 different genes.  They found 18 that were likely to predict whether or not cancer would recur or whether the patient would benefit from 5-FU chemotherapy.  The 18 gene assay was then validated by testing tumor tissue from more than 1,400 patients who were part of the QUASAR (Quick And Simple And Reliable) clinical trial.  QUASAR had randomized patients to either receive chemotherapy with 5-FU and leucovorin or further treatment surgery.

The QUASAR validation showed that recurrence scores could accurately predict who had a low, intermediate, or high risk of recurrence.  The score also reliably predicted disease-free and overall survival.  Scores were ranked from 0 to 100 with the lowest scores having an 8 to 10 percent risk of recurring and the highest scores a 20 to 25 percent chance of coming back.

About 25 to 30 percent of patients with colon cancer are diagnosed with stage II cancer where the tumor has gone to the outermost layers of the colon or through the colon wall but has not yet spread to nearby lymph nodes.  Chemotherapy has only a modest benefit for stage II patients, reducing the absolute risk of recurrence for the whole group by about 3 percent.

Being able to decide which patients will have cancer come back, usually as a spread to a distant organ (metastasis), and might benefit from chemotherapy has been a challenging decision for doctors and patients alike.

David Kerr, MD, DSc, professor of cancer medicine at the University of Oxford and lead author of the QUASAR validation study, which will be presented at the upcoming meeting of the American Society of Clinical Oncology in Orlando, explained yesterday:

Having this well-validated molecular signature to predict risk of colon cancer recurrence will have a significant impact on the way we treat patients with this disease.This assay gives physicians important clinical information that will enable them to better select the right patients for the right treatment at the right time.” Scientists have validated the accuracy of a 12 gene test  to estimate the risk that stage II colon cancer will return within three years.  Using the test, stage II patients can be identified as having low, intermediate, or high risk of recurrence.

You can listen to Dr. Kerr’s presentation yesterday at the ASCO Press Briefing.

Two clinical factors — T4 stage and mismatch repair status — remained independent predictors of recurrence.  In the QUASAR study T4 tumors, which have grown through the wall of the colon and into nearby tissues, had a poor prognosis nearly doubled the risk of recurrence.  On the other hand, patients whose tumors showed deficient mismatch repair or microsatellite instability (MSI) had a 70 percent reduction in the risk of their cancer coming back.

T4 tumors and those with deficient mismatch repair genes account for only about 25 percent of stage II colon cancers.  For other tumors, the recurrence score can be valuable in clinical decision-making, according to Dr. Kerr.

Carlea Bauman, President of C3:Colorectal Cancer Coalition, reflected on possibilities of the new test.

Patients with stage II colon cancer are often faced with tough decisions about treatment. These findings will help patients and their physicians make decisions based on each patient’s potential risk. This is critically important to patients facing treatment options that can be life-altering. Patients want the assurance that they are receiving the most appropriate course of treatment for their individual disease.

Genomic Health, in Redwood, CA, plans to make a commercial version of the 12-gene Oncotype DX colon cancer test available to physicians and patients in early 2010.

SOURCE: Kerr et al., Abstract #4000, A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study, ASCO 2009 Annual Meeting Abstracts.


Disclosure: C3 has accepted funding for projects and educational programs from Genomic Health in the form of unrestricted educational grants. C3 has ultimate authority over website content.

Share on FacebookTweet about this on TwitterPin on PinterestShare on Google+Email this to someone

Comments

    • Kate Murphy says

      Yes, the gene test is on the market.

      It is called the Oncotype DX Colon Cancer Assay, and it is available from Genomic Health.

      The test is done on tissue from your tumor which was preserved after your surgery. Your doctor will need to order it and arrange for tissue samples to be sent to Genomic Health. There is information on the Genomic Health website to help doctors arrange the test.

      We do not know the cost of the test, but it is now covered by Medicare and some insurances. Genomic Health will help your and your doctor find out if your insurance covers it.

      If you don’t have insurance or insurance doesn’t cover Oncotype DX Colon Cancer Assay, Genomic Health has a patient assistance program to help with costs. Call the Genomic Health Customer Service at 866-ONCOTYPE (866-662-6897). They can also tell you the cost of the test.

Leave a Reply